METHODS FOR THE DIAGNOSIS AND FOR THE TREATMENT OF CRITICALLY ILL PATIENTS WITH ENDOTHELIN, ENDOTHELIN AGONISTS AND ADRENOMEDULLIN ANTAGONISTS
    2.
    发明申请
    METHODS FOR THE DIAGNOSIS AND FOR THE TREATMENT OF CRITICALLY ILL PATIENTS WITH ENDOTHELIN, ENDOTHELIN AGONISTS AND ADRENOMEDULLIN ANTAGONISTS 有权
    用内皮素,内皮素激动剂和ADRENOMEDULLIN ANTAGONISTS诊断和治疗关键病人的方法

    公开(公告)号:US20100209433A1

    公开(公告)日:2010-08-19

    申请号:US12095675

    申请日:2005-12-01

    摘要: The ratio of concentrations of pro-adrenomedullin (pro-ADM)/pro-endothelin (pro-END) immunoreactivity in body fluids of critically ill patients is used for the diagnosis, course control and prognosis, including an assessment of the mortality risk, of severe life threatening diseases. Further, a treatment of critically ill patients having high levels of pro-ADM but insufficient levels of pro-END immunoreactivities with a medicament comprising vasoconstrictive endothelin or its precursors, and/or endothelin agonists or adrenomedullin antagonists is provided.Submitted herewith is a sequence listing in computer readable form for entry into the present application. Also enclosed is a pdf copy of the as-filed sequence listing and a Checker Program report indicating that the text file of the sequence listing contains no errors.

    摘要翻译: 危重病人体液中前肾上腺髓质素(pro-adrenomedullin(pro-ADM)/ pro-endothelin(pro-end))免疫反应性的比例用于诊断,病程控制和预后,包括对死亡风险的评估 严重的威胁生命的疾病。 此外,提供了治疗具有高水平的pro-ADM但具有包含血管收缩性内皮素或其前体的药物和/或内皮素激动剂或肾上腺髓质素拮抗剂的前-THT免疫反应性水平不足的危重患者。 本文提供的是用于输入本申请的计算机可读形式的序列表。 还附有所提交的序列表的pdf副本以及指示序列表的文本文件不包含错误的检查程序报告。

    In vitro method for the detection of early-stage liver damage
    5.
    发明授权
    In vitro method for the detection of early-stage liver damage 有权
    用于检测早期肝损伤的体外方法

    公开(公告)号:US08252548B2

    公开(公告)日:2012-08-28

    申请号:US12299829

    申请日:2007-05-08

    IPC分类号: C12Q1/34

    CPC分类号: G01N33/6893 G01N2800/085

    摘要: Disclosed is an in vitro method for the identification and the concomitant monitoring of the therapy and cure of drug-induced or addictive substance-induced liver damage, in which the occurrence of the human enzyme carbamoyl synthase 1 (CPS 1) or its concentration is determined in serum or plasma samples from patients who are being or have been treated with potentially liver-damaging drugs, or from people who take harmful stimulants and addictive substances or are exposed to hepatotoxic substances.

    摘要翻译: 公开了一种用于鉴定和伴随监测药物诱导或成瘾物质诱导的肝损伤的治疗和治疗的体外方法,其中确定人酶氨基甲酰合酶1(CPS 1)或其浓度的发生 来自患有或已经被潜在的肝损伤药物治疗的患者的血清或血浆样品,或者来自服用有害兴奋剂和成瘾物质或暴露于肝毒性物质的人。